Cognitive Profile and Mental Health in Adult Phenylketonuria: A PKU-COBESO Study

Rianne Jahja*, Jaap J. van der Meere, Amanda M. Legemaat, M. Estela Rubio-Gozalbo, Floris C. Hofstede, Ans T. van der Ploeg, Janneke G. Langendonk, Stephan C. J. Huijbregts, Leo M. J. de Sonneville, Annet M. Bosch, Carla E. M. Hollak, Martijn C. G. J. Brouwers, Maaike C. de Vries, Mirian C. H. Janssen, Francjan J. van Spronsen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Web of Science)

Abstract

Objective: Despite early dietary treatment phenylketonuria patients have lower IQ and poorer executive functions compared to healthy controls. Cognitive problems in phenylketonuria have often been associated with phenylalanine levels. The present study examined the cognitive profile and mental health in adult phenylketonuria, in relation to phenylalanine levels and tetrahydrobiopterin treatment. Method: Fifty-seven early treated adult patients with phenylketonuria and 57 healthy matched controls (18-40 years) performed IQ subtests and executive function tests from the Amsterdam Neuropsychological Tasks. They also completed the Adult Self-Report on mental health problems. Analyses of variance were performed to examine group differences. Results: Patients with phenylketonuria had normal IQs although lower than controls. They performed poorer on working memory, inhibitory control, and sustained attention tasks. Patients reported Depressive and Avoidant Personality problems more frequently. Specifically, patients with childhood and lifetime phenylalanine >= 360 mu mol/L had poorer cognitive and mental health outcomes than controls. In a subset of patients, comparisons between patients on and off tetrahydrobiopterin showed that nontetrahydrobiopterin users (matched for childhood, pretreatment phenylalanine) were slower (on number of tasks) and reported more mental health problems. Conclusions: Adult patients had lower IQ and poorer executive functions than controls, resembling problems observed in younger patients with phenylketonuria, as well as more internalizing problems. Group differences and phenylalanine-outcome associations were smaller than those observed in younger populations. A subset of nontetrahydrobiopterin users, matched for childhood phenylalanine level, had a poorer outcome on some tests than tetrahydrobiopterin users, which might indicate an impact of tetrahydrobiopterin treatment beyond lowering phenylalanine. However, clinical relevance needs further investigation.

Original languageEnglish
Pages (from-to)437-447
Number of pages11
JournalNeuropsychology
Volume31
Issue number4
DOIs
Publication statusPublished - May 2017

Keywords

  • phenylketonuria
  • adults
  • executive functions
  • mental health
  • tetrahydrobiopterin
  • EARLY-TREATED PHENYLKETONURIA
  • EXECUTIVE FUNCTION IMPAIRMENT
  • BLOOD PHENYLALANINE LEVELS
  • TETRAHYDROBIOPTERIN BH4
  • CHILDREN
  • ADOLESCENTS
  • SAPROPTERIN
  • METAANALYSIS
  • INDIVIDUALS
  • INHIBITION

Cite this